CGEM Q2 2025 Earnings — Cullinan Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CGEMCullinan Therapeutics, Inc.

$894M

Q2 2025 Earnings

Healthcare Medical - Pharmaceuticals

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$76M

Net Income

-$70M

EPS (Diluted)

$-1.19

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$58M

Free Cash Flow

-$58M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$520M

Total Liabilities

$28M

Stockholders' Equity

$492M

Cash & Equivalents

$73M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	-$77,000	+100.0%
Operating Income	-$76M	-$50M	-51.5%
Net Income	-$70M	-$42M	-66.7%